About Entrez
Text Version
Entrez PubMed Overview Help | FAQ Tutorials New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut My NCBI
Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

Note: Performing your original search, ***ketorolac ocular analgesic***, in PubMed will retrieve *52* citations.

Display Abstract Show 20 Sort by Send to
All: 1 Review: 0

1: J Pharm Sci. 1996 Apr;85(4):415-8. Related Articles, Links

Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.

Madhu C, Rix PJ, Shackleton MJ, Nguyen TG, Tang-Liu DD.

Department of Pharmacokinetics, Allergan, Inc., Irvine, CA 92713-9534, USA.

This study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability (Focular) of ketorolac tromethamine after ocular instillation to normal and de-epithelialized corneas of rabbits both in vitro and in vivo. The in vitro Focular of the formulations was measured in flow-through perfusion chambers. For in vivo studies, a 35 microL dose of 0.5% ketorolac tromethamine with or without BAK/EDTA was instilled into rabbit eyes with intact or de-epithelialized corneas. At 0.5, 1, 2, 4, 6, and 8 h postdose, rabbits were euthanized, and the corneas and aqueous humor were collected from both eyes. The ketorolac concentrations from both in vivo and in vitro samples were quantified by reversed-phase high-performance liquid chromatography. The in vitro study results indicated that BAK/EDTA statistically significantly increased the Focular of ketorolac through de-epithelialized corneas but not through intact corneas. The in vivo study results showed that BAK/EDTA had no effect on the Focular of ketorolac in rabbits with intact corneas, based on the values of the area under the aqueous humor concentration versus time curves (AUC0-6h) of ketorolac. As expected, de-epithelialization of the corneas produced a faster and greater ocular absorption of ketorolac as evidenced by the smaller Tmax and larger AUC values compared to those for the intact corneas in vivo. However, BAK/EDTA decreased the ocular absorption of ketorolac in rabbits with de-epithelialized corneas. The half-lives (t 1/2) of ketorolac in corneal tissue and aqueous humor were longer in rabbits with intact corneas than those in rabbits with de-epithelialized corneas. In conclusion, the in vivo Focular of ketorolac was not altered by BAK/EDTA in rabbits with intact corneas, but it was decreased by BAK/EDTA in rabbits with de-epithelialized corneas. Therefore, the formulation with ketorolac alone may be better as a post-operative ocular analgesic.

PMID: 8901080 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

NMDA antagonists as potential analgesic drugs

by Dalip J.S. Sirinathsinghji (Editor), Ray G. Hill (Editor)

READY TO BUY?
Add to Shopping Cart
or
Sign in to turn on 1-Click ordering.

BOOK INFORMATION
Explore this book
buying info
editorial reviews
See more by the authors
all books by Dalip J.S. Sirinathsinghji
all books by Ray G. Hill
Share your thoughts



Publisher: learn how customers can search inside this book.

List Price: ~~CDN$ 100.03~~
Our Price: **CDN$ 134.13** & this item ships for **FREE with Super Saver Shipping.** See details
You Save: CDN$ 65.80 (33%)

Usually ships within 3 to 6 weeks.

See larger picture

Product Details

Hardcover - 191 pages 1 edition (April 29, 2002)
Language: English
Birkhauser (Progress in Inflammation Research) ; ISBN: 3764360119

Editorial Reviews

Book Description

There is now considerable preclinical evidence that glutamate acting via the **NMDA** receptor is involved in the transmission of nociceptive information and in the triggering mechanisms for hyperalgesia and allodynia. This evidence allows rational development of a new class of **analgesic** drugs that act as antagonists of the **NMDA** receptor, supported by

emerging evidence with existing excitatory amino acid antagonists.Leading scientists in excitatory amino acid and analgesia research have compiled in this volume the most recent information on molecular biology, physiology and pharmacology of **NMDA** receptors, their neuroanatomical localisation within specific neural pathways involved in nociception, and experimental and clinical evidence demonstrating the potential of receptor antagonists of **NMDA** and other excitatory amino acids in the treatment of pain states.

Book Info

Merck, Sharp & Dohme Research Laboratories, Essex, UK. Presents current information on molecular biology, physiology, and pharmacology of **NMDA** receptors, their neuroanatomical localization within specific neural pathways involved in nociception, and more.

See all editorial reviews...

Look for books like **NMDA** antagonists as potential **analgesic** drugs by subject:

Browse for Books in:

- Subjects > Professional & Technical > Medical > Pharmacology > Clinical
- Subjects > Engineering > Bioengineering > Biochemistry
- Subjects > Medicine > Basic Science > Biochemistry
- Subjects > Medicine > Basic Science > Microbiology
- Subjects > Medicine > Basic Science > Physiology
- Subjects > Medicine > General
- Subjects > Medicine > Pharmacology
- Subjects > Medicine > Pharmacology > General
- Subjects > Medicine > Pharmacology > Pain Medicine
- Subjects > Medicine > Internal Medicine > Neurology

Search for books by subject:

- Antagonists
- Clinical Pharmacology
- Excitatory amino acids
- Health, Beauty, Fitness
- Medical
- Medical / Biochemistry
- Medical / General
- Medical / Nursing
- Medical / Pharmacology
- Methyl aspartate
- Microbiology
- Molecular aspects
- Neurology - General
- Pain
- Pain (Medical Aspects)
- Pain Medicine
- Pharmacology
- Receptors

Find books matching ALL checked subjects

i.e., each book must be in subject 1 AND subject 2 AND ...

Top of Page : **NMDA** antagonists as potential **analgesic** drugs

Search | **Browse Subjects** | **Bestsellers** | **New & Future Releases** | **En français** | **Make money** | **Textbooks**

Pol. J. Pharmacol., 1999, 51, 223-231
ISSN 1230-6002

Go to: Contents | Previous Article | Next Article | PJP - Home Page |

CLINICALLY AVAILABLE NMDA ANTAGONIST, MEMANTINE, ATTENUATES TOLERANCE TO ANALGESIC EFFECTS OF MORPHINE IN A MOUSE TAIL FLICK TEST

Piotr Popik[#], *Ewa Kozela*
Department of Biochemistry, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31-343 Kraków, Poland

*Clinically available **NMDA antagonist**, memantine, attenuates tolerance to **analgesic** effects of morphine in a mouse tail flick test.* P. POPIK, E. KOZELA. Pol. J. Pharmacol., 1999, 51, 223-231.

Converging lines of evidence indicate that N-methyl-d-aspartate (**NMDA**) receptor antagonists attenuate the development of morphine tolerance tested in antinociception assays in rodents. The present study extends these findings to the effects of clinically available **NMDA** receptor **antagonist**, memantine. Male Albino Swiss mice were tested for analgesia using the tail-flick apparatus. Preliminary experiment was designed to find out the optimal dose of morphine and the number of injections that would produce tolerance to its **analgesic** effects. In the main experiment, during the development of tolerance period (6 days), mice received 10 mg/kg *sc* b.i.d. morphine injections in the animal room (non-associative tolerance). This treatment resulted in 5.8 fold rightward shift of morphine cumulative dose-response effect from 3.39 mg/kg on day 1 to 16.19 mg/kg on day 8 of the experiment. Memantine pretreatment (5 and 10 mg/kg, but not 2.5 mg/kg), given 30 min prior to each morphine dose during the development of tolerance period, inhibited the rightward shift of morphine cumulative dose-response curve. Thus, pretreatment with memantine at doses of 2.5, 5 and 10 mg/kg resulted in ED_{50} values of 12.13, 4.74 and 1.95 mg/kg, respectively, corresponding to 3.35, 1.02 and 0.94 fold changes. These data indicate that low affinity, clinically available **NMDA** receptor **antagonist**, memantine, may be used to inhibit the development of morphine tolerance.

***Key words: NMDA antagonist**, memantine, analgesia, tolerance, morphine*

[#] correspondence

Back to: Top | PJP - Home Page |